[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"AC Camargo Cancer Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":228},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,39,70,100,126,147,175,204],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100645412","neosent-early-anti-pd-1-therapy-in-high-risk-stage-ii-melanoma-100645412",false,"NCT07680699","NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma","NEOSENT - Early Anti-PD-1 Therapy In Patients With High-Risk Stage II Melanoma And\u002FOr Microsatellitosis: An Ambispective Observational Cohort Study","NEOSENT","Inclusion Criteria:\n\n\\- Adults (≥18 years) with histologically confirmed cutaneous melanoma stage IIB or IIC or stage III (N1c), managed in routine clinical practice.\n\nExclusion Criteria:\n\n* Patients without sufficient clinical or follow-up data.\n* Patients who do not provide informed consent (for prospective cohort).","ALL","18 Years",{"count":20,"type":21},250,"ESTIMATED","OBSERVATIONAL","This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma.\n\nPatients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study.\n\nThe study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice.\n\nNo treatments are assigned as part of the study.",[25],"Cutaneous Melanoma","RECRUITING","2026-06-26",{"date":29,"type":30},"2026-07-02","ACTUAL",{"date":32,"type":30},"2025-04-23",{"date":34,"type":21},"2027-05",{"name":36,"class":37},"AC Camargo Cancer Center","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":38},"100613611","use-of-preoperative-postbiotic-supplementation-in-colorectal-cancer-surgery-100613611","NCT07268846","Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery","Randomized Clinical Trial on the Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery","POSBIO-CRC","Inclusion Criteria:\n\n* Individuals diagnosed with malignant neoplasm of the large intestine, specifically adenocarcinoma.\n* Patients over 18 years of age, of both sexes.\n* Patients who agree to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Emergency or urgent surgeries.\n* Cytoreductive surgeries involving intraoperative intraperitoneal chemotherapy.\n* Extended surgeries for the treatment of recurrent tumors.",{"count":48,"type":21},164,"INTERVENTIONAL",[51],"NA","The treatment of colorectal cancer, in the absence of metastases, is primarily based on surgical removal. Colorectal surgery, which involves resecting part of the intestine and restoring intestinal continuity, carries a risk of complications. This study aims to evaluate whether oral supplementation with a postbiotic at a dose of 900 mg for 7 days prior to surgery reduces the rate of postoperative complications.",[54],"Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)",[56,57,58,59,60,61],"Colorectal cancer surgery","Postbiotic","colorectal cancer","intestinal microbiota","nutritional intervention","inflammation","2025-12-04",{"date":64,"type":30},"2025-12-08",{"date":66,"type":30},"2025-06-01",{"date":68,"type":21},"2027-06-01",{"name":36,"class":37},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":49,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":38},"100614881","study-to-evaluate-the-use-of-surgical-gloves-for-the-prevention-of-oxaliplatin-induced-peripheral-neuropathy-100614881","NCT07285356","Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy","GLOX-PEN: Phase II Clinical Trial to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy","GLOX-PEN","Inclusion Criteria:\n\n* Patients aged 18 years or older who have provided written informed consent.\n* Colon adenocarcinoma with high-risk stage III (pT4pN2) or stage IV.\n* Oxaliplatin-based treatment in the context of localized or metastatic disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n\nExclusion Criteria:\n\n* Pre-existing neuropathy.\n* Uncontrolled diabetes.\n* known glove allergies.\n* Prior treatment with paclitaxel, docetaxel or oxaliplatin.",{"count":79,"type":21},84,[51],"The primary objective of this randomized clinical trial is to assess whether the use of surgical gloves during treatment can prevent the occurrence of oxaliplatin-induced peripheral neuropathy.",[83,84],"Colon Cancer","Oxaliplatin-induced Peripheral Neuropathy",[86,87,88,89,90,91],"oxaliplatin-induced peripheral neuropathy","Peripheral Neuropathy","Oxaliplatin","Surgical Gloves","Body Mass Index (BMI)","Sarcopenia","2025-12-02",{"date":94,"type":30},"2025-12-16",{"date":96,"type":30},"2025-10-06",{"date":98,"type":21},"2026-09-18",{"name":36,"class":37},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":49,"phases":109,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":38},"100577041","phase-2-intestinal-microbiome-modulation-with-antibiotics-in-the-neoadjuvant-treatment-of-locally-advanced-rectal-cancer-100577041","NCT06793137","Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","Phase II Trial for Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n* Patients over 18 years old with middle and lower rectal adenocarcinoma, classified as locally advanced or where the tumor´s location necessitates rectal amputation surgery;\n* Tumors located below the peritoneal reflection, as determined by MRI, will be defined as middle and lower rectum;\n* Patients eligible for rectal amputation will be those with tumor whose distal margin is less than 2,0cm from the pectineal line, as determined by rectoscopy, or less than 2,0cm from the anorectal ring by palpation or MRI.\n* Patients with middle rectum cancer candidates for radiotherapy as part of neoadjuvant treatment will be included according to the following criteria: mesorectal fascia compromised by direct extension of the primary tumor or by an affected lymph node; cT4 tumors.\n\nExclusion Criteria:\n\n* Patients without performance status for total neoadjuvant treatment;\n* Histologies other than adenocarcinoma;\n* Adenocarcinomas with a microsatellite instability phenotype, as determined by immunohistochemistry;\n* Patients with middle rectal tumors who are not indicated for radiotherapy in the neoadjuvant treatment regimen, according to the institutional protocol (tumors cT3N0, with free mesorectal fascia; cT1-3 N+, with free mesorectal fascia).",{"count":108,"type":21},100,[110],"PHASE2","Colorectal cancer is the second most common malignancy worldwide and one-third of these tumors are located in the rectum. The treatment may involve up to three modalities: radiotherapy, chemotherapy, and surgery. For several years, thanks mainly to Brazilian researchers, subgroups of patients have been selected for non-surgical treatment when chemoradiotherapy induces a complete clinical response. These treatment regimens have reached a plateau leading researchers to seek strategies that can increase response rates. Intestinal microbiota studies have shown that an overpopulation of certain anaerobic bacteria is generally associated with poorer treatment response. No study has attempted to intervene in the gut microbiota to increase the complete response rate in rectal cancer. The proposal of the investigators aims to modulate the intestinal microbiota through a phase 2 clinical trial, with the use of metronidazole as the intervention .",[113],"Rectal Cancer, Adenocarcinoma",[115,116,117],"Total Neoadjuvant Therapy","Intestinal microbiota","Locally advanced rectal cancer","2025-01-27",{"date":120,"type":30},"2025-01-29",{"date":122,"type":30},"2024-07-22",{"date":124,"type":21},"2026-04-30",{"name":36,"class":37},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":133,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":49,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":38},"100532609","the-effects-of-dance-for-breast-cancer-patients-undergoing-surgical-treatment-100532609","NCT06215027","The Effects of Dance for Breast Cancer Patients Undergoing Surgical Treatment","Os Efeitos da dança Como Recurso terapêutico em Pacientes Com câncer de Mama Submetidas a Tratamento cirúrgico","Inclusion Criteria:\n\n* patients diagnosed with breast cancer\n* undergone surgical resection\n* after medical referral for physiotherapy\n* and physiotherapeutic assessment\n\nExclusion Criteria:\n\n* patients with another previous oncological diagnosis\n* previous neuromuscular diseases\n* patients who do not agree to take part in the study\n* or the impossibility of carrying out the muscle strength assessment and\u002For other assessments","FEMALE",{"count":135,"type":21},30,[51],"The goal of this non randomized clinical trial, with pre- and post-intervention evaluation, longitudinal, with prospective data collection is to evaluate the effects of dance as a therapeutic intervention in breast cancer patients undergoing surgical treatment.",[139],"Breast Cancer",{"date":141,"type":30},"2025-01-28",{"date":143,"type":30},"2024-02-01",{"date":145,"type":21},"2026-05-30",{"name":36,"class":37},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":133,"minAge":18,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":49,"phases":158,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},"100313867","sentinel-node-mapping-in-high-risk-endometrial-cancer-100313867","NCT03366051","Sentinel Node Mapping in High Risk Endometrial Cancer","Sentinel Node Mapping Versus Sentinel Node Mapping With Systematic Lymphadenectomy in High Risk Endometrial Cancer: a Open Label, Non-inferiority, Randomized Trial.","ALICE","Inclusion Criteria:\n\n* High grade histologies (endometrioid grade 3, serous, clear cell and carcinosarcoma)\n* Endometrioid grades 1 or 2 with myometrial invasion of ≥50%\n* Endometrioid grades 1 or 2 with cervical invasion\n* Clinically suitable to receive systematic lymphadenectomy\n* Consent statement\n\nExclusion Criteria:\n\n* Previous hysterectomy in other institution\n* Presence of extra-uterine disease (peritoneal, visceral or suspicious lymph node metastasis)\n* Previous pelvic node dissection","75 Years",{"count":157,"type":21},178,[51],"This study will evaluate the role of systematic lymphadenectomy after sentinel node (SLN) mapping in high risk endometrial cancer (high grade histologies or deep myometrial invasion). The participants will be randomized in a non-inferiority controlled trial in 2 groups: SLN mapping or SLN mapping followed by systematic lymphadenectomy.",[161,162],"Endometrial Cancer","Lymph Node Metastases",[161,164,165],"Sentinel Lymph Node","Lymphadenectomy","2024-07-29",{"date":168,"type":30},"2024-07-30",{"date":170,"type":30},"2017-12-22",{"date":172,"type":21},"2024-12-20",{"name":36,"class":37},5,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":49,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":203},"100552384","phase-2-everolimus-5-mg-vs-10-mgdaily-for-patients-with-neuroendocrine-tumors-100552384","NCT06472388","Everolimus 5 mg vs 10 mg\u002FDaily for Patients With Neuroendocrine Tumors","Randomized Phase II Trial of Everolimus 5 mg vs 10 mg\u002FDaily for Patients With Advanced Neuroendocrine Tumors","EVENET","Inclusion Criteria:\n\n* Histological confirmation of well-differentiated Grade 1\u002FGrade 2 NET from gastrointestinal, pancreatic, pulmonary or unknown primary sites.\n* Metastatic or locally advanced and unresectable disease, measurable by images\n* Disease progression by RECIST 1.1 in the last 6 months assessed by local investigators\n* At least one previous line of systemic treatment (suspended for more than 3 weeks).\n* Eastern Cooperative Oncology Group (ECOG) 0-2 o Good organ function:\n\n  * Hemoglobin \\> 8 g\u002FdL\n  * Neutrophils ≥ 1,500\u002Fmm³\n  * Platelets \\> 90,000\u002Fmm³\n  * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN \\[upper limit of normal\\] or ≤ 5 x ULN for patients with liver metastases\n  * Bilirubin ≤ 1.5 x ULN, creatinine \\\u003C 1.5 mg\u002FdL\n\nExclusion Criteria:\n\n* Aggressive disease requiring cytotoxic therapy\n* Severe\u002Funcontrolled comorbid conditions that deem participant unfit for everolimus therapy, as per investigators' judgement.\n* MiNEN","16 Years",{"count":108,"type":21},[110],"Everolimus is approved in many countries to treat patients with advanced\u002Fmetastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different types of NET. However, it is can cause severe adverse effects. Phase I trial demonstrated that a dose of 5mg\u002Fday\u002Fweek was sufficient to inhibit cell proliferation by blocking the mTOR pathway.\n\nThis is a randomized, open-label, phase II near-equivalence clinical trial of oral everolimus 5 mg vs 10 mg oral\u002Fdaily and continuously in patients with Grade 1 or Grade 2 metastatic NET, with tumor progression or intolerance to at least one line of treatment and with radiological disease progression within 6 months.",[188,189,190,191,192,193,194],"Neuroendocrine Tumors","Progression","Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2","Neuroendocrine Tumor of Pancreas","Neuroendocrine Tumor of the Lung","Neuroendocrine Tumor Carcinoid","2024-06-18",{"date":197,"type":30},"2024-06-25",{"date":199,"type":30},"2024-04-24",{"date":201,"type":21},"2026-12-31",{"name":36,"class":37},2,{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":49,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":38},"100438725","phase-2-circulating-tumor-cells-and-treatment-de-escalation-after-neoadjuvant-therapy-for-her2-positive-breast-cancer-100438725","NCT04993014","Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer","Circulating Tumor Cells and Adjuvant Treatment De-escalation After Neoadjuvant Therapy With Trastuzumab and Pertuzumab for HER2 Positive Early Breast Cancer","HER2Cell","Inclusion Criteria:\n\n* HER2 positive breast cancer (hormone receptors positive or negative)\n* Stage I to III\n* Indication for neoadjuvant therapy with chemo (any regimen) + trastuzumab + pertuzumab\n* Breast surgery after neoadjuvant therapy\n* Preserved coagnition\n* ECOG 0-3\n* For the randomization phase: pathological complete response (ypT0\u002FypTis and ypN0)\n* Agreement on participation and signature of de ICF\n\nExclusion Criteria:\n\n* Contradindication for trastuzumab or pertuzumab\n* Adjuvant chemotherapy. Hormone therapy is allowed\n* Second primary tumor \\\u003C 5 years, with an exception for treated non-melanoma skin cancer, and in situ cervical cancer",{"count":213,"type":21},80,[110],"Phase II unicentric randomized trial which will include early HER2 positive breast cancer patients, candidate to neoadjuvant therapy with trastuzumab and pertuzumab. Circulating tumor cells will be collected at neoadjuvant therapy baseline.\n\nPatients with pathological complete response will be randomized in 1:1 ratio for adjuvant trastuzumab (arm A) versus trastuzumab + pertuzumab (arm B) in a two factorial design: group A, with HER2 positive CTCs and group B, with HER2 negative\u002Fabsent CTCs.",[217,218,219],"Breast Neoplasms","HER2-positive Breast Cancer","Circulating Tumor Cell","2021-07-28",{"date":222,"type":30},"2021-08-06",{"date":224,"type":30},"2021-03-01",{"date":226,"type":21},"2028-04-30",{"name":36,"class":37},""]